CA2587883A1 - Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma - Google Patents
Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma Download PDFInfo
- Publication number
- CA2587883A1 CA2587883A1 CA002587883A CA2587883A CA2587883A1 CA 2587883 A1 CA2587883 A1 CA 2587883A1 CA 002587883 A CA002587883 A CA 002587883A CA 2587883 A CA2587883 A CA 2587883A CA 2587883 A1 CA2587883 A1 CA 2587883A1
- Authority
- CA
- Canada
- Prior art keywords
- use according
- polysaccharide
- glycosaminoglycan
- phosphatidylethanolamine
- nothing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract 5
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract 5
- 208000006673 asthma Diseases 0.000 title claims abstract 5
- 208000019693 Lung disease Diseases 0.000 title 1
- 201000009961 allergic asthma Diseases 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 150000002632 lipids Chemical class 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- 239000000539 dimer Substances 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 8
- 239000000178 monomer Substances 0.000 claims abstract 8
- 229920000642 polymer Polymers 0.000 claims abstract 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 18
- 150000004676 glycans Chemical group 0.000 claims 18
- 229920001282 polysaccharide Polymers 0.000 claims 18
- 239000005017 polysaccharide Substances 0.000 claims 18
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 17
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 12
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 12
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 12
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 6
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 6
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 6
- 229960001231 choline Drugs 0.000 claims 6
- 229940031098 ethanolamine Drugs 0.000 claims 6
- 229960005150 glycerol Drugs 0.000 claims 6
- 229920000669 heparin Polymers 0.000 claims 6
- 229960002897 heparin Drugs 0.000 claims 6
- 229920002674 hyaluronan Polymers 0.000 claims 6
- 229960003160 hyaluronic acid Drugs 0.000 claims 6
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 6
- 229960000367 inositol Drugs 0.000 claims 6
- 150000003904 phospholipids Chemical class 0.000 claims 6
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 6
- 229960001153 serine Drugs 0.000 claims 6
- 125000006850 spacer group Chemical group 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
This invention provides for the use of a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof, for the preparation of a composition for treating a subject suffering from asthma, allergic rhinitis, or chronic obstructive pulmonary disease. This invention also provides for the use of a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof, for the preparation of a composition for preventing asthma, allergic rhinitis, or chronic obstructive pulmonary disease in a subject.
Description
USE OF LIPID
Claims (48)
1. Use of a compound represented by the structure of the general formula (A):
wherein L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and n is a number from 1 to 1000 for the preparation of a composition to treat asthma.
wherein L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and n is a number from 1 to 1000 for the preparation of a composition to treat asthma.
2. The use according to claim 1, wherein X is a polysaccharide.
3. The use according to claim 2, wherein said polysaccharide is carboxymethylcellulose.
4. The use according to claim 2, wherein said polysaccharide is a glycosaminoglycan.
5. The use according to claim 4, wherein said glycosaminoglycan is hyaluronic acid.
6. The use according to claim 4, wherein said glycosaminoglycan is heparin.
7. The use according to claim 1, wherein L is phosphatidylethanolamine.
8. The use according to claim 7, wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.
9. Use of a compound represented by the structure of the general formula (A):
wherein L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and n is a number from 1 to 1000 for the preparation of a composition to prevent asthma.
wherein L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and n is a number from 1 to 1000 for the preparation of a composition to prevent asthma.
10. The use according to claim 9, wherein X is a polysaccharide.
11. The use according to claim 10, wherein said polysaccharide is carboxymethylcellulose.
12. The use according to claim 10, wherein said polysaccharide is a glycosaminoglycan.
13. The use according to claim 12, wherein said glycosaminoglycan is hyaluronic acid.
14. The use according to claim 12, wherein said glycosaminoglycan is heparin.
15. The use according to claim 9, wherein L is phosphatidylethanolamine.
16. The use according to claim 15, wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.
17. Use of a compound represented by the structure of the general formula (A):
wherein L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and n is a number from 1 to 1000 for the preparation of a composition to treat allergic rhinitis.
wherein L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and n is a number from 1 to 1000 for the preparation of a composition to treat allergic rhinitis.
18. The use according to claim 17, wherein X is a polysaccharide.
19. The use according to claim 18, wherein said polysaccharide is carboxymethylcellulose.
20. The use according to claim 18, wherein said polysaccharide is a glycosaminoglycan.
21. The use according to claim 20, wherein said glycosaminoglycan is hyaluronic acid.
22. The use according to claim 20, wherein said glycosarninoglycan is heparin.
23. The use according to claim 17, wherein L is phosphatidylethanolamine.
24. The use according to claim 23, wherein said phosphatidylethanolamine is dipalmitoyl pho sphatidylethanolamine.
25. Use of a compound represented by the structure of the general formula (A):
wherein L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and n is a number from 1 to 1000 for the preparation of a composition to prevent allergic rhinitis.
wherein L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and n is a number from 1 to 1000 for the preparation of a composition to prevent allergic rhinitis.
26. The use according to claim 25, wherein X is a polysaccharide.
27. The use according to claim 26, wherein said polysaccharide is carboxymethylcellulose.
28. The use according to claim 26, wherein said polysaccharide is a glycosaminoglycan.
29. The use according to claim 28, wherein said glycosaminoglycan is hyaluronic acid.
30. The use according to claim 28, wherein said glycosaminoglycan is heparin.
31. The use according to claim 25, wherein L is phosphatidylethanolamine.
32. The use according to claim 31, wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.
33. Use of a compound represented by the structure of the general formula (A):
wherein L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and n is a number from 1 to 1000 for the preparation of a composition to treat chronic obstructive pulmonary disease.
wherein L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and n is a number from 1 to 1000 for the preparation of a composition to treat chronic obstructive pulmonary disease.
34. The use according to claim 33, wherein X is a polysaccharide.
35. The use according to claim 34, wherein said polysaccharide is carboxymethylcellulose.
36. The use according to claim 34, wherein said polysaccharide is a glycosaminoglycan.
37. The use according to claim 36, wherein said glycosaminoglycan is hyaluronic acid.
38. The use according to claim 36, wherein said glycosaminoglycan is heparin.
39. The use according to claim 33, wherein L is phosphatidylethanolamine.
40. The use according to claim 39, wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.
41. Use of a compound represented by the structure of the general formula (A):
wherein L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and n is a number from 1 to 1000 for the preparation of a composition to prevent chronic obstructive pulmonary disease.
wherein L is a lipid or a phospholipid;
Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer; and n is a number from 1 to 1000 for the preparation of a composition to prevent chronic obstructive pulmonary disease.
42. The use according to claim 41, wherein X is a polysaccharide.
43. The use according to claim 42, wherein said polysaccharide is carboxymethylcellulose.
44. The use according to claim 42, wherein said polysaccharide is a glycosaminoglycan.
45. The use according to claim 44, wherein said glycosaminoglycan is hyaluronic acid.
46. The use according to claim 44, wherein said glycosaminoglycan is heparin.
47. The use according to claim 41, wherein L is phosphatidylethanolamine.
48. The use according to claim 47, wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/989,606 US7811999B2 (en) | 2000-01-10 | 2004-11-17 | Use of lipid conjugates in the treatment of diseases |
| US10/989,607 US7772196B2 (en) | 2000-01-10 | 2004-11-17 | Use of lipid conjugates in the treatment of diseases |
| US10/989,606 | 2004-11-17 | ||
| US10/989,607 | 2004-11-17 | ||
| PCT/US2005/006591 WO2005084307A2 (en) | 2004-03-02 | 2005-03-02 | Use of lipid conjugates in the treatment of disease |
| USPCT/US2005/006591 | 2005-03-02 | ||
| PCT/IL2005/001225 WO2006054304A2 (en) | 2004-11-17 | 2005-11-17 | Use of lipid conjugates in the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2587883A1 true CA2587883A1 (en) | 2006-05-26 |
Family
ID=39619055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002587883A Abandoned CA2587883A1 (en) | 2004-11-17 | 2005-11-17 | Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1819345A4 (en) |
| JP (2) | JP2008520650A (en) |
| CN (1) | CN101175499B (en) |
| AU (1) | AU2005305456B2 (en) |
| BR (1) | BRPI0516810A (en) |
| CA (1) | CA2587883A1 (en) |
| EA (1) | EA012138B1 (en) |
| IL (3) | IL183227A0 (en) |
| MX (1) | MX2007005975A (en) |
| WO (1) | WO2006054304A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090325876A1 (en) * | 2004-09-29 | 2009-12-31 | Saul Yedgar | Use of lipid conjugates in the treatment of diseases associated with vasculature |
| WO2008100912A1 (en) * | 2007-02-12 | 2008-08-21 | The General Hospital Corporation | Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists |
| CN102458420A (en) * | 2009-05-11 | 2012-05-16 | 以色列耶路撒冷希伯来大学伊索研究发展公司 | Lipid-polymer conjugates, their preparation and uses thereof |
| CA2925546C (en) | 2012-10-29 | 2022-06-14 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating mucosal tissue disorders |
| WO2015005459A1 (en) * | 2013-07-10 | 2015-01-15 | 生化学工業株式会社 | Pharmaceutical composition for respiratory administration |
| JP2019518798A (en) * | 2016-06-27 | 2019-07-04 | オハイオ・ステイト・イノベーション・ファウンデーション | Liponucleotide based ARDS treatment |
| AU2017362500B2 (en) | 2016-11-17 | 2024-09-26 | Renovion, Inc. | Treatment of Respiratory Tract Diseases and Infections with Ascorbic Acid Compositions |
| WO2019099946A1 (en) | 2017-11-17 | 2019-05-23 | Renovion, Inc. | Stable ascorbic acid compositions and methods of using the same |
| MX2024008001A (en) | 2022-01-04 | 2024-07-12 | Renovion Inc | Aqueous solution comprising a glutathione salt. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL84252A (en) * | 1987-10-23 | 1994-02-27 | Yissum Res Dev Co | Phospholipase inhibiting compositions |
| JPH0232013A (en) * | 1988-07-20 | 1990-02-01 | Denki Kagaku Kogyo Kk | Nasal drop |
| US6022866A (en) * | 1991-07-03 | 2000-02-08 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
| ES2044781B1 (en) * | 1992-04-14 | 1994-10-01 | Menarini Lab | PROCEDURE FOR THE PREPARATION OF NEW AMIDES WITH PHOSPHOLIPASE A2 INHIBITING ACTION |
| JP3714683B2 (en) * | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | Anti-rheumatic agent |
| DK0785773T3 (en) * | 1994-10-14 | 2001-01-29 | Liposome Co Inc | Etherlipid liposomes and their therapeutic use |
| US6180596B1 (en) * | 1995-05-18 | 2001-01-30 | Wisconsin Alumni Research Foundation | Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities |
| US6071532A (en) * | 1996-10-15 | 2000-06-06 | Emory University | Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof |
| JPH11147901A (en) * | 1997-11-19 | 1999-06-02 | Maruho Co Ltd | Kallikrein-kinin system inhibitor |
| US6162787A (en) * | 1999-04-02 | 2000-12-19 | Immudyne, Inc. | Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions |
| US7101859B2 (en) * | 2000-01-10 | 2006-09-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
| CA2397016C (en) * | 2000-01-10 | 2011-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
| US7141552B2 (en) * | 2000-01-10 | 2006-11-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
-
2005
- 2005-11-17 CA CA002587883A patent/CA2587883A1/en not_active Abandoned
- 2005-11-17 JP JP2007542507A patent/JP2008520650A/en active Pending
- 2005-11-17 AU AU2005305456A patent/AU2005305456B2/en not_active Ceased
- 2005-11-17 EP EP05808267A patent/EP1819345A4/en not_active Withdrawn
- 2005-11-17 MX MX2007005975A patent/MX2007005975A/en active IP Right Grant
- 2005-11-17 WO PCT/IL2005/001225 patent/WO2006054304A2/en active Application Filing
- 2005-11-17 CN CN2005800467713A patent/CN101175499B/en not_active Expired - Fee Related
- 2005-11-17 EA EA200701077A patent/EA012138B1/en not_active IP Right Cessation
- 2005-11-17 BR BRPI0516810-4A patent/BRPI0516810A/en not_active Application Discontinuation
-
2007
- 2007-05-15 IL IL183227A patent/IL183227A0/en unknown
-
2011
- 2011-04-07 IL IL212214A patent/IL212214A0/en unknown
- 2011-04-07 IL IL212215A patent/IL212215A0/en unknown
- 2011-09-13 JP JP2011199088A patent/JP2012001559A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101175499B (en) | 2010-12-22 |
| CN101175499A (en) | 2008-05-07 |
| EA200701077A1 (en) | 2008-04-28 |
| EP1819345A4 (en) | 2012-04-18 |
| JP2012001559A (en) | 2012-01-05 |
| AU2005305456B2 (en) | 2011-05-19 |
| MX2007005975A (en) | 2007-10-08 |
| IL183227A0 (en) | 2007-08-19 |
| JP2008520650A (en) | 2008-06-19 |
| AU2005305456A1 (en) | 2006-05-26 |
| EP1819345A2 (en) | 2007-08-22 |
| EA012138B1 (en) | 2009-08-28 |
| WO2006054304A2 (en) | 2006-05-26 |
| IL212215A0 (en) | 2011-06-30 |
| BRPI0516810A (en) | 2008-09-23 |
| IL212214A0 (en) | 2011-06-30 |
| WO2006054304A3 (en) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2587883A1 (en) | Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma | |
| BR0316264A (en) | Drug for treatment of chronic obstructive pulmonary disease | |
| US8691857B2 (en) | EP4 agonist | |
| RU2007107935A (en) | POLYSULPHATED GLYCOSIDES AND THEIR SALTS | |
| JP2001512443A (en) | Arginine silicate inositol complex and use thereof | |
| Gautier et al. | Innate immune response triggered by triacyl lipid A is dependent on phospholipid transfer protein (PLTP) gene expression | |
| KR20150085509A (en) | Compounds and compositions for use in the prevention and treatment of inflammation-related disorders, pain and fever, skin disorders, cancer and precancerous conditions thereof | |
| WO2007019131A3 (en) | Use of lipid conjugates in cystic fibrosis and applications thereof | |
| RU2564414C2 (en) | New ep4 agonist | |
| US11013811B2 (en) | Lipid-polymer conjugates, their preparation and uses thereof | |
| JP2009522218A (en) | Pharmaceutical formulations for the treatment of osteoarthritis | |
| WO2010131116A3 (en) | Use of lipid conjugates in the treatment of diseases associated with vasculature | |
| AU2013202151B2 (en) | Lipid conjugates in the treatment of chronic rhinosinusitis | |
| JP2015533128A5 (en) | ||
| CN1471923A (en) | Spray for treating asthma and its preparing method | |
| EP2545909A1 (en) | Combination of D-Amino Acids and Lipoteichoic Acid | |
| US20180086827A1 (en) | Therapeutics and methods of treating fibroproliferative diseases | |
| KR20070070215A (en) | A new use for very low molecular weight heparins | |
| TWI686201B (en) | Sub-nanometer gold sticker and methods for protecting against endotoxin-induced sepsis thereof | |
| US20140005115A1 (en) | Lipid conjugates in the treatment of bronchitis | |
| AU2021374726A9 (en) | Compositions comprising methyl cyclodextrins for the treatment and/or prevention of hepatic steatosis | |
| CN101035545A (en) | Pulmonary administration of an antithrombotic compound | |
| TW201422231A (en) | Antagonizing heparin with salicylamide compounds and histamine blocking agents | |
| WO2014136116A1 (en) | Lipid conjugates in the treatment of bronchitis | |
| AU2014200908A1 (en) | Use of lipid conjugates in the treatment of disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20140604 |